Royal Bank Of Canada Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $21.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its target price decreased by Royal Bank Of Canada from $22.00 to $21.00 in a report issued on Wednesday morning,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock.

APLS has been the subject of a number of other reports. Mizuho dropped their target price on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Wells Fargo & Company dropped their price objective on shares of Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating for the company in a research report on Tuesday, January 20th. JPMorgan Chase & Co. reduced their price objective on Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Needham & Company LLC lowered their target price on Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Finally, Wolfe Research began coverage on Apellis Pharmaceuticals in a research report on Thursday, November 6th. They set a “peer perform” rating for the company. Twelve equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $32.61.

Apellis Pharmaceuticals Price Performance

Apellis Pharmaceuticals stock opened at $20.96 on Wednesday. The business’s fifty day moving average is $23.00 and its two-hundred day moving average is $23.79. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.10 and a current ratio of 3.14. The firm has a market cap of $2.68 billion, a P/E ratio of 161.24 and a beta of 0.26. Apellis Pharmaceuticals has a 52 week low of $16.10 and a 52 week high of $30.48.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.86. The business had revenue of $199.91 million during the quarter, compared to analysts’ expectations of $199.28 million. Apellis Pharmaceuticals had a return on equity of 8.20% and a net margin of 2.23%.The firm’s revenue for the quarter was down 5.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.29) earnings per share. Equities research analysts forecast that Apellis Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, CAO James George Chopas sold 2,064 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $44,933.28. Following the completion of the sale, the chief accounting officer owned 49,805 shares in the company, valued at approximately $1,084,254.85. This represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Pascal Deschatelets sold 5,928 shares of the stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $129,052.56. Following the completion of the transaction, the insider directly owned 1,151,382 shares in the company, valued at $25,065,586.14. The trade was a 0.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 120,537 shares of company stock valued at $2,608,532 over the last quarter. 6.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Jones Financial Companies Lllp increased its stake in Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after purchasing an additional 1,373 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of Apellis Pharmaceuticals by 141.2% in the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after buying an additional 1,570 shares during the period. Allworth Financial LP grew its holdings in shares of Apellis Pharmaceuticals by 64.1% in the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after buying an additional 857 shares during the period. Quantbot Technologies LP bought a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $64,000. Finally, EverSource Wealth Advisors LLC raised its stake in Apellis Pharmaceuticals by 338.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after buying an additional 4,191 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

Key Stories Impacting Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright retains a “Buy” rating and a $48 price target, signaling continued analyst conviction in Apellis’ longer‑term upside. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
• Positive Sentiment: HC Wainwright published a long‑range forecast that includes a return to positive EPS by FY2030 (EPS ~$1.97), which underpins the firm’s $48 target and suggests expected recovery beyond the near term. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
• Neutral Sentiment: Apellis’ latest quarter delivered an EPS beat ($0.47 vs. expectations) but revenue was down ~6% year‑over‑year — a mixed fundamental print that reduces downside surprise risk but highlights demand pressure.
• Neutral Sentiment: Reported short‑interest data in recent filings appears anomalous (zero / NaN entries) and is not a reliable signal of investor positioning at this time.
• Negative Sentiment: HC Wainwright sharply lowered near‑term and multi‑year EPS forecasts (e.g., FY2026 cut to ~($2.19) from ($1.69); FY2027, FY2028 and several quarterly estimates were also reduced), increasing near‑term earnings uncertainty and pressuring the stock. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
• Negative Sentiment: Citigroup trimmed its price target to $44, signaling reduced upside in the nearer term and contributing to downward pressure. Citigroup Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $44.00
• Negative Sentiment: Wedbush and Royal Bank of Canada also lowered expectations, adding to the analyst‑driven sell pressure. Wedbush Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Royal Bank Of Canada Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.